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Abstract
Bifidobacteria have received significant attention due to their contribution to human gut health and the use of specific
strains as probiotics. It is thus not surprising that there has also been significant interest with respect to their antibiotic
resistance profile. Numerous culture-based studies have demonstrated that bifidobacteria are resistant to the majority
of aminoglycosides, but are sensitive to β-lactams. However, limited research exists with respect to the genetic basis
for the resistance of bifidobacteria to aminoglycosides. Here we performed an in-depth in silico analysis of putative
Bifidobacterium-encoded aminoglycoside resistance proteins and β-lactamases and assess the contribution of these
proteins to antibiotic resistance. The in silico-based screen detected putative aminoglycoside and β-lactam
resistance proteins across the Bifidobacterium genus. Laboratory-based investigations of a number of representative
bifidobacteria strains confirmed that despite containing putative β-lactamases, these strains were sensitive to β-
lactams. In contrast, all strains were resistant to the aminoglycosides tested. To assess the contribution of genes
encoding putative aminoglycoside resistance proteins in Bifidobacterium sp. two genes, namely Bbr_0651 and
Bbr_1586, were targeted for insertional inactivation in B. breve UCC2003. As compared to the wild-type, the
UCC2003 insertion mutant strains exhibited decreased resistance to gentamycin, kanamycin and streptomycin. This
study highlights the associated risks of relying on the in silico assignment of gene function. Although several putative
β-lactam resistance proteins are located in bifidobacteria, their presence does not coincide with resistance to these
antibiotics. In contrast however, this approach has resulted in the identification of two loci that contribute to the
aminoglycoside resistance of B. breve UCC2003 and, potentially, many other bifidobacteria.
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Introduction
Following the discovery of penicillin by Alexander Fleming
[1], exponential antibiotic discovery and development occurred
which revolutionized medicine. However, during this same
period, target bacteria developed sophisticated mechanisms of
resistance against many of the most commonly prescribed
antibiotics [2]. It is thus not surprising that considerable efforts
have been and are still being made to investigate the genetic
mechanisms involved in the transfer, acquisition and
expression of antibiotic resistance genes, in order to curtail or
prevent the further development of resistance [3,4].
The mechanisms underlying resistance to aminoglycosides
and to β-lactams are among those that have been the focus of
particular attention. Briefly, aminoglycosides are a family of
broad spectrum antibiotics that were first reported in 1944 [5],
whose bactericidal activity results from their binding to the 30S
subunit of the prokaryotic ribosome and the subsequent
impairment of protein synthesis [5,6]. Aminoglycoside
resistance can be mediated through reduced aminoglycoside
uptake [7], or through enzymatic modification of the
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aminoglycoside through the activity of the N-acetyltransferases
(AAC), O-nucleotidyltransferases (ANT) or O-
phosphotransferases (APH). Aminoglycoside resistance genes
have been classified based on the enzymatic modification
mechanism used by the resultant protein and the chemical
position at which the aminoglycoside is modified [8].
β-lactam antibiotics are a class of broad spectrum antibiotics
which include the penicillins and cephalosporins [9]. β-lactams
inhibit bacteria by their interference with normal cell wall
synthesis, via disruption of the final cross-linking stage of cell
wall peptidoglycan formation, resulting in a significantly
weakened cell wall polymer, ultimately leading to bacterial cell
death [10-12]. β-lactam resistance can arise through mutation
of target penicillin binding proteins (PBPs; [13,14]), as well as
through the production of β-lactamases [15], which catalyze the
hydrolysis of the eponymous β-lactam rings present in β-lactam
antibiotics, rendering the antibiotic inactive. β-lactamase
classification has undergone significant rounds of change from
the initial Ambler classification proposed in 1973 [16] and the
classification schemes of Bush and colleagues [17-20].
The antibiotic resistance genes of pathogenic bacteria have
been the focus of greatest attention. Similarly, antibiotic
sensitivity is regarded as a desirable trait among candidate
probiotic strains for the feed [21] and human [22,23] markets.
Such a phenotype ensures that their consumption does not
further increase the risk of antibiotic resistance gene
dissemination, especially in situations where such genes are
located on mobile genetic elements. Gut-associated
bifidobacteria are generally viewed as beneficial microbes and
many strains have been attributed with health-promoting
characteristics [24-27]. Thus, it is not surprising that many
bifidobacteria are used, or have been studied with a view to
their potential use, as probiotics in functional foods [28]. As a
consequence, there has been considerable interest in
determining if certain bifidobacteria possess antibiotic
resistance genes [29-32]. These studies established that the
tested bifidobacteria strains are generally resistant to
aminoglycoside antibiotics [33], but are sensitive to β-lactams
[29,31,34,35]. In a previous study, we found that combined
ampicillin and gentamycin treatment in infants, caused a
significant decrease in the proportion of bifidobacteria present
4 weeks after antibiotic administration ceased, while also
significantly altering the bifidobacteria species present [36]. We
were therefore interested in investigating differences in the
distribution of genes encoding β-lactam or aminoglycoside
resistance proteins among members of the Bifidobacterium
genus.
To date little is known about the genetic mechanisms that
underlie aminoglycoside resistance in bifidobacteria. Despite
the existence of some specific studies [32,37,38], the presence
of antibiotic resistance genes has been more frequently
inferred through the annotation of DNA sequences and the
identification of genes bearing some homology to genes
previously assigned as being potential resistance determinants.
Given the risks associated with relying exclusively on rapid in
silico assignments, here we present an in-depth bioinformatic
analysis of putative β-lactam and aminoglycoside resistance
proteins that are Bifidobacterium-encoded. We have
investigated if a correlation exists between these proteins and
antibiotic resistance and, in the case of aminoglycoside
resistance, have demonstrated the contribution of the assigned
resistance genes to this phenotype.
Materials and Methods
NCBI database search for Bifidobacterium-associated
β-lactam and aminoglycoside resistance proteins
Using the NCBI protein database, a search for putative β-
lactamases and aminoglycoside resistance proteins associated
with bifidobacteria was completed using the terms ‘beta-
lactamase’ and ‘Bifidobacterium’ (searched on 28/8/12) and
‘aminoglycoside’ and ‘Bifidobacterium’ (search completed on
29/8/12). This approach was taken so that all such proteins,
regardless of the basis upon which they were assigned, would
be revealed. Following the removal of duplicates and
sequences that did not originate from Bifidobacterium, all
remaining sequences were used as drivers for subsequent
rounds of BLAST investigations. All subsequent distinct
sequences detected were employed for additional BLAST-
based investigations until a finalized list was achieved.
Additionally, further BLAST-based investigations using known
β-lactamase and aminoglycoside resistance proteins as drivers
were completed to ensure no additional sequences were
overlooked.
Classification of β-lactamases and aminoglycoside
resistance protein sequences from bifidobacteria
Putative Bifidobacterium-associated β-lactamase and
aminoglycoside resistance proteins were subjected to in silico
analysis with a view to classifying them using the Ambler
method for β-lactamases [17], or assigning them into one of the
3 main enzyme modification groups associated with
aminoglycoside resistance [8]. To this end, the putative
Bifidobacterium-associated resistance determinants were
aligned (MegAlign Clustal W, LaserGene) against
representative sequences from each class (A-D for the β-
lactamases) and from each of the 3 enzyme groups (AAC, APH
and ANT for the aminoglycosides) [19,20] (Table 1).
Laboratory based assessments of antibiotic resistance
The antibiotic susceptibility of bifidobacteria strains was
investigated in a number of different ways. Disc diffusion
assays were carried out according to the British Society for
Antimicrobial Chemotherapy (BSAC) guidelines [39-41]. Briefly
the bifidobacteria strains were cultured overnight anaerobically
and delivered onto Iso-Sensitest agar plates (Oxoid, Fisher
Scientific, Dublin, Ireland) using a swab in three directions.
Antimicrobial discs containing ampicillin (25 µg), penicillin (10
µg) (VWR International, Dublin, Ireland), neomycin (30 µg),
gentamycin (200 µg), kanamycin (30 µg) and streptomycin (25
µg) (Fisher Scientific, Dublin, Ireland) were dispensed manually
onto the agar plates. Following anaerobic incubation at 37°C
for 48 hours, the diameters of the zones of inhibition (mm) were
measured. All tests were carried out in triplicate.
Antibiotic Resistance in Bifidobacterium
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Minimum inhibitory concentration tests (MICs) using 4
aminoglycosides i.e. neomycin, gentamycin, streptomycin and
kanamycin (Sigma Aldrich, Dublin, Ireland) were performed as
per the micro-dilution method, as described in detail by others
[42]. Briefly, bifidobacteria were grown overnight anaerobically
at 37°C in MRS broth supplemented with 0.05% cysteine
(Sigma Aldrich, Wexford, Ireland). Cultures were adjusted to an
OD600 of 0.1 (≈ 1 x 105 cfu/ml) in fresh MRS broth (media pH
6.8). Stock solutions of each of the aminoglycoside antibiotics
were prepared in sterile distilled water and a 2-fold dilution
series was performed. An inoculum of 100 µl of culture was
added to each well of the 96 well plate (resulting in a final
concentration of ≈ 5 x 104 cfu/ml) (Sarstedt, Wexford, Ireland).
Additionally, each 96 well plate contained positive (MRS +
culture) and negative controls (MRS only), and tests were
carried out in triplicate. Plates were incubated anaerobically
(using anaerobic gas jars and Anaerocult P anaerobic gas pack
inserts (Merck Millipore Ltd, Cork, Ireland)) at 37°C for 24
hours and the MIC was determined as the lowest concentration
of antimicrobial agent at which no visible growth was recorded.
MICs were also carried out on E. coli XL1-blue which had been
transformed with plasmid-encoded copies of the putative
aminoglycoside resistance genes Bbr_0651, Bbr_1586 and
Bbr_0651+0650. Protocols were as described above except
that LB broth (pH 7.1) (Difco, Fisher Scientific, Ireland) was
used for culturing and growth conditions were 24 hours
aerobically at 37°C.
To test for β-lactamase activity, nitrocefin tests were
performed as previously described [43,44], i.e. β-lactamase
nitrocefin sticks (Fisher Scientific, Ireland), were dipped into a
single colony for each species being tested and assessed for
1-2 minutes and again after 15 minutes for the appearance of a
pink colour, indicative of β-lactamase activity. Staphylococcus
aureus DPC 5286 was used as the positive control.
Disruption of the Bbr_0651 and Bbr_1586 genes from
B. breve UCC2003
Site specific homologous recombination was used to disrupt
2 genes present in B. breve UCC2003, namely Bbr_0651 and
Bbr_1586, using protocols similar to those previously described
[45,46]. Briefly, internal fragments of Bbr_0651 and Bbr_1586,
were amplified by PCR using specifically designed primers
(MWG Eurofins, Germany) (Table S1), resulting in 500bp and
400bp products respectively. These fragments were cloned into
the pORI19 vector and a tetracycline resistance marker (tetW
gene) from the pAM5 vector [47] was subcloned to generate
the plasmids pORI19-tet-0651 and pORI19-tet-1586 (Table 2).
The correct sequence of each cloned insert was verified by
sequencing (Source BioScience, Dublin, Ireland).
Being derivatives of pORI19 these plasmids cannot replicate
in B. breve UCC2003, due to a lack of a functional replication
protein [48], and instead are utilised with a view to integrating
into and disrupting target genes. To facilitate methylation, the
pORI19 plasmids were introduced via electroporation into
EC101 E. coli cells containing pNZ-M.BbrII-M.BbrIII. The
resulting methylated pORI19-tet-0651 and pORI19-tet-1586
constructs were electroporated into B. breve UCC2003.
Transformants were selected based on presence of
tetracycline resistance. Transformants were expected to carry
Bbr_0651 or Bbr_1586 gene disruptions, respectively. To verify
the suspected chromosomal integration of these pORI19
constructs, colony PCRs were performed on a selection of
tetracycline resistant transformants, using a forward primer
Table 1. Representative sequences used as drivers for Blast based investigations into Bifidobacterium-associated
aminoglycoside resistant proteins and β-lactamases.
Aminoglycoside resistance gene
classification groups Representative sequences   β-lactamase gene classes   Representative gene name   
Representative gene accession
number
APH M20305 Class A TEM1 YP_209323.1
 V00618  TEM1 AFN82055.1
 M29953  SHV-2 YP_001966240.1
 X07753  PSE YP_005086938.1
APH (6’) X05648  CepA YP_210868.1
 X01702  Sme_1 CAA82281.1
AAC 3 X01385  Bla KPC YP_003754012.1
 M55426 Class B IMP-1 YP_005980003.1
 M22999  VIM-1 YP_003813035.1
AAC-Ia & Ib L06157  CcrA YP_004735262.1
AAC 6’ Ic M94066  L1 YP_006185056.1
ANT X02340  CphA YP_004391384.1
 X04555  Sph1 YP_005188946.1
  Class C AMP C AAG59351.1
  Class D OXA-1 AFB82783.1
   OXA-10 YP_001715358.1
   OXA-23 YP_002317955.1
doi: 10.1371/journal.pone.0082653.t001
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upstream of the integration region and a reverse primer based
on pORI19 (Table S1).
Complementation studies
DNA fragments containing the gene Bbr_1586 and its native
promoter region were generated by PCR amplification from B.
breve UCC2003 chromosomal DNA, using Pfu Ultra II Hotstart
Mastermix (Agilent Technologies, Cork, Ireland) and sequence
specific primers (Table S1). The amplicons and the pBC1.2
plasmid were digested with HindIII and XbaI (Roche
Diagnostics, Sussex, UK) and subsequently ligated using T4
DNA ligase (Roche Diagnostics, Sussex, UK). This resulted in
the complementation plasmid pBC1.2-Bbr_1586 (Table 2). The
dialysed ligations were electroporated into E. coli XL1-blue and
the resulting plasmids verified by PCR and restriction digest
analysis. Finally, the plasmid pBC1.2-Bbr_1586 was
electroporated into competent B. breve UCC2003-1586-tet
cells. Transformants from the complemented strain were
selected and the presence of the construct confirmed.
Studies of wild-type B. breve UCC2003 with additional
copies of aminoglycoside resistance genes
Studies were also completed to investigate if the addition of
extra plasmid-encoded copies of the putative aminoglycoside
resistance genes Bbr_0651, Bbr_0651+0650 or Bbr_1586
would result in enhanced resistance of the wild-type B. breve
UCC2003. Competent B. breve UCC2003 cells were prepared
and transformed with the constructs pBC1.2-0651,
pBC1.2-0651+0650 or pBC1.2-1586. Transformants were
selected and the presence of the plasmid inserts was
confirmed.
Table 2. Bacterial strains and plasmids used in this study.
Strain or plasmid Relevant characteristics Ref or Source
E.coli strains   
EC101 Cloning host, repA+ , kanr Law et al. (1995)
XL1-blue Tetr Stratagene
XL1-blue-pBC1.2-Bbr_0651 Heterologous expression of Bbr_0651 This study
XL1-blue-pBC1.2-Bbr_0651+0650 Heterologous expression of Bbr_0651+0650 This study
XL1-blue-pBC1.2-Bbr_1586 Heterologous expression of Bbr_1586 This study
B. breve strains   
UCC2003 Isolated from nursing stool Mazé et al. (2007)
UCC2003-0651-tet pORI19-0651-tet insertion mutant of B. breve UCC2003 This study
UCC2003-1586-tet pORI19-1586-tet insertion mutant of B. breve UCC2003 This study
B. breve UCC2003-gosG pORI19-tet-Bbr_0529 insertion mutant of UCC2003 O’ Connell Motherway et al. (2013)
UCC2003-1586-tet-pBC1.2-Bbr_1586 pORI19-1586-tet insertion mutant complemented strain of B. breve UCC2003 This study
UCC2003-pBC1.2-Bbr_0651 pBC1.2-Bbr_0651 construct in B. breve UCC2003 This study
UCC2003-pBC1.2-Bbr_0651+0650 pBC1.2-Bbr_0651+0650 construct in B. breve UCC2003 This study
UCC2003-pBC1.2-Bbr_1586 pBC1.2-Bbr_1586 construct in B. breve UCC2003 This study
UCC2003-pBC1.2 B. breve UCC2003 harbouring pBC1.2 This study
Bifidobacteria strains   
B. gallicum DSM 20093 Contains putative β-lactamase protein Teagasc Culture Collection
B. animalis subsp. lactis Bb12 Contains putative β-lactamase and AG resistance proteins Teagasc Culture Collection
B. angulatum DSM 20098 Contains putative β-lactamase and AG resistance proteins Teagasc Culture Collection
B. pseudocatenulatum DSM 20438 Contains putative β-lactamase and AG resistance proteins Teagasc Culture Collection
B. breve DSM 20213 Contains putative β-lactamase and AG resistance proteins Teagasc Culture Collection
B. breve UCC2003 Contains putative β-lactamase and AG resistance proteins Teagasc Culture Collection
Plasmids   
pAM5 pBC1-puC19-Tcr Alvarez-Martín et al. (2007)
pORI19 Emr, repA-, ori+, cloning vector Law et al. (1995)
pORI19-tet-0651 Internal 500bp fragments of Bbr_0651 and tetW cloned in pORI19 This study
pORI19-tet-1586 Internal 400bp fragments of Bbr_1586 and tetW cloned in pORI19 This study
pBC1.2 pBC1-pSC101-Cmr Alvarez-Martín et al. (2007)
pBC1.2-0651 Bbr_0651 cloned in pBC1.2 This study
pBC1.2-0651+0650 Bbr_0651+Bbr_0650 cloned in pBC1.2 This study
pBC1.2-1586 Bbr_1586 cloned in pBC1.2 This study
AG: aminoglycoside
doi: 10.1371/journal.pone.0082653.t002
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Heterologous expression of putative aminoglycoside
resistance genes in E. coli
Plasmid-encoded copies of the entire putative
aminoglycoside resistance genes Bbr_0651, Bbr_0651+0650
and Bbr_1586, along with their native promoters were
transformed via electroporation into competent E. coli XL1-
blue. Following confirmation of the presence of the correct
plasmid insert in the transformants, MIC assays were
completed, using the protocol outlined above.
Results
Putative β-lactamases associated with Bifidobacterium
species
In order to identify Bifidobacterium-associated proteins which
have been annotated, or possibly mis-annotated, as β-
lactamases, the NCBI protein database was screened for
Bifidobacterium-associated proteins which had been annotated
as β-lactamases or which had been noted to contain β-
lactamase associated motifs (searched on 28/8/12). The
proteins identified were in turn employed as drivers for BLAST
analysis (of non-redundant proteins), to identify and assess the
distribution of related Bifidobacterium-associated proteins.
Subsequent rounds of BLAST analysis, employing the related,
yet distinct, protein sequences as drivers, ultimately resulted in
saturation. To ensure that other potential β-lactamases were
not overlooked, further BLAST-based investigations, using
known β-lactamase proteins as drivers, were also carried out to
screen all publically available Bifidobacterium genomes.
The resultant proteins fell into a number of different
categories (Table 3). The most common protein was that
annotated variably as a metallo-beta-lactamase family protein,
a metal-dependent hydrolase or ribonuclease J such as
HMPREF0168_0178 from B. dentium ATCC 27679. This
protein is conserved, at high (>90%) percentage identity,
across almost all publically available Bifidobacterium genomes
and is a member of the protein family 07521 (Pfam07521;
RNA-metabolising metallo-beta-lactamases). A considerable
number of other proteins are linked by virtue of containing
domains typical of Pfam13354 (a β-lactamase enzyme family of
proteins). These proteins are not highly conserved, with distinct
subgroups such as those represented by HMPREF0168_1872
from B. dentium ATCC 27679, BBB_1387 from B. bifidum
BGN4, BBB_1559 from B. bifidum BGN4 and Bbr_0236 from
B. breve UCC2003, respectively, being apparent. Other unique
members of Pfam13354 are BIFADO_ 0224 (B. adolescentis
L2-32), BLJ0695 (B. longum subsp. longum JDM 301) and
BAD_1308 (B. adolescentis ATCC 15703). B. dentium
genomes also share a conserved protein, representative of
Pfam00144 (a β-lactamase family), such as
HMPREF0168_1378 from B. dentium ATCC 27679. B.
catenulatum DSM 16992 (BIFCAT_01331) and B.
pseudocatenulatum DSM 20438 (BIFPSEUDO_02501) also
contained proteins from this family (PF00144) which were
highly conserved (>90% identity). However, these were distinct
from other PF00144 family proteins associated with B. dentium
ATCC 27679. The remaining protein of potential relevance is
Blon_2358 from B. longum subsp. infantis ATCC 15697. This
protein has been assigned as a β-lactamase but, unlike the
other proteins referred to above, its closest homologues are not
other Bifidobacterium-associated proteins but, rather, are
proteins that have been found in the genomes of various
clostridia, enterococci and lactobacilli. In addition to containing
domains corresponding to Pfam07251, this protein is also
representative of Pfam12706, i.e. the lactamase_B_2 family of
proteins.
Putative aminoglycoside resistance proteins
associated with Bifidobacterium species
An identical approach to that taken for the β-lactamases, was
taken to identify Bifidobacterium-associated proteins which had
been annotated, or potentially mis-annotated, as
aminoglycoside resistance proteins. A search of the NCBI
protein database using the terms ‘aminoglycoside’ and
‘Bifidobacterium’ was completed (search completed on
29/8/12). The analysis revealed that putative aminoglycoside
resistance proteins are widely distributed across the
Bifidobacterium genus, and are particularly common among
strains of B. longum (Table 4). Furthermore, it appears that all
putative Bifidobacterium-associated aminoglycoside resistance
proteins can be broadly classified into 3 groups i.e. those
containing proteins of the family Pfam01636
(phosphotransferase enzyme family), proteins containing a
protein kinase family domain, c109925, or those which appear
to contain both. While some of these proteins appeared to be
highly conserved within or across bifidobacteria strains and
species, some proteins appear to be much more distantly
related. The results indicated that only one putative protein was
solely associated with the protein family Pfam01636, namely
BBMN_137 from B. longum BBMN68. In a number of other
instances proteins which were members of Pfam01636 and
which also contained the c109925 domain, were noted. In
some cases these proteins were annotated as aminoglycoside
phosphotransferases, e.g. BIF_01665 (B. animalis subsp. lactis
Bb12), while in other cases they were annotated as
desulfatases, e.g. BL_1642 (B. longum NCC 2705), or
homoserine kinases, e.g. BBMN_1674 (B. longum BBMN8). In
addition, B. bifidum BGN4 BBB_0978 and B. bifidum S17
BBIF_0997 also exhibit characteristics of Pfam01636 and
possess a protein kinase domain, but have been annotated as
an N-acetyl hexosamine kinase and a mucin desulfatase,
respectively. In this instance, laboratory-based investigations
have previously established that this gene does indeed encode
N-acetyl hexosamine kinase [49]. Some sequences which were
annotated as being from Pfam01636 and also contained a
protein kinase family domain were highly conserved (with
>90% percentage identity) e.g. BLD_1766 (B. longum DJ010A)
and BLIG_01601 from B. longum subsp. infantis CCUG
52486). However, in other instances, these proteins were more
distantly related e.g. BBIF_0997 (B. bifidum S17) and
Bbr_1586 (B. breve UCC2003).
Proteins containing a protein kinase family domain, c109925,
only and also annotated as aminoglycoside
phosphotransferase or hypothetical proteins are also widely
distributed across Bifidobacterium species. Some of these,
such as BLD_0109 (B. longum DJ010A), Blon_0773 (B.
Antibiotic Resistance in Bifidobacterium
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Table 3. Bifidobacterium derived β-lactamase protein sequences.
Bifidobacterium strain
Accession
number*  Gene name Assigned as Pfam
B. dentium ATCC 27679 ZP_07457312.1a HMPREF0168_1872 Conserved hypothetical protein PF13354
 ZP_07456818.1b HMPREF0168_1378 β-lactamase PF00144
 ZP_07455619.1d HMPREF0168_0178 Hypothetical protein Metal dependent hydrolase withPF07521
B. dentium Bd1 YP_003359579.1a BDP_0063 Hypothetical protein PF13354
 YP_003360049.1b BDP_0556 Hypothetical protein PF00144
 YP_003361167.1d BDP_1754 Hypothetical protein Metal dependent hydrolase withPF07521
B. dentium ATCC 27678 ZP_02917480.1a BIFDEN_00760 Hypothetical protein PF11354
 ZP_02916953.1b BIFDEN_00213 Hypothetical protein PF00144
 ZP_02918099.1d BIFDEN_01398 Hypothetical protein Metal dependent hydrolase withPF07521
B. gallicum DSM 20093 ZP_05965566.1d BIFGAL_03078 Metallo-beta-lactamase family protein Metal dependent hydrolase withPF07521
B. adolescentis L2-32 ZP_02027818.1 BIFADO_0224 Hypothetical protein PF13354
 ZP_02029327.1d BIFADO_01784 Hypothetical protein PF07521
B. animalis subsp. lactis Bb12 YP_005575727.1d BIF_01983 Hydrolase Metal dependent hydrolase withPF07521
B. animalis subsp. animalis ATCC 25527 YP_006280466.1d BANAN_06475 Hypothetical protein Metal dependent hydrolase withPF07521
B. animalis subsp. lactis AD011 YP_002469408.1d BLA_0533 β-lactamase-like protein Metal dependent hydrolase withPF07521
B. bifidum BGN4 YP_006394858.1f BBB_1387 Penicillin binding protein PF13354
 YP_006395029.1g BBB_1559 β-lactamase PF13354
 YP_006393888.1d BBB_0414 Ribonuclease J Metal dependent hydrolase withPF07521
B. bifidum NCIMB 41171 ZP_07803038.1g BBNG_01520 Conserved hypothetical protein PF13354
 ZP_07803204.1f BBNG_01686 β-lactamase PF13354
 ZP_07801866.1d BBNG_00347 Conserved hypothetical protein Metal dependent hydrolase withPF07521
B. bifidum PRL 2010 YP_003971645.1g BBPR_1582 β-lactamase PF13354
 YP_003971485.1f BBPR_1404 β-lactamase PF13354
 YP_003970583.1d BBPR_0437 Metal-dependent hydrolase Metal dependent hydrolase withPF07521
B. longum subsp. longum JDM 301 YP_003660997.1 BLJ_0695 β-lactamase PF13354
B. adolescentis ATCC 15703 YP_910171.1 BAD_1308 β-lactamase PF13354
 YP_910159.1d BAD_1296 Hypothetical protein PF07521
B. breve UCC2003 ABE94945.1e Bbr_0236 Conserved hypothetical protein with β-lactamase motif PF13354
 ABE95207.1d Bbr_0510 Metal-dependent hydrolase Metal dependent hydrolase withPF07521
B. breve ACS 071 VSch8b YP_005582166.1e HMPREF9228_0250 Hypothetical protein PF13354
 YP_005583195.1d HMPREF9228_1387 Hypothetical protein Metal dependent hydrolase withPF07521
B. breve DSM 20213 ZP_06595304.1e BIFBRE_03112 Putative β-lactamase PF13354
 ZP_06595596.1d BIFBRE_03411 Metallo-beta-lactamase family protein Metal dependent hydrolase withPF07521
B. breve CECT 7263 EHS86772.1e CECT7263_10968 Putative β-lactamase PF13354
 EHS85412.1d CECT7263_11981 Metallo-beta-lactamase family protein Metal dependent hydrolase withPF07521
B. catenulatum DSM 16992 ZP_03324536.1c BIFCAT_01331 Hypothetical protein PF00144
 ZP_03324350.1d BIFCAT_01138 Hypothetical protein Metal dependent hydrolase withPF07521
B. bifidum S17 YP_003939138.1f BBIF_1359 β-lactamase PF13354
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longum subsp. infantis ATCC 15697) and BLJ_1379 (B.
longum subsp. longum JDM301), are highly conserved while
others, such as BLJ_1379 (B. longum subsp. longum JDM301)
and BIFANG_02451 (B. angulatum DSM 20098), are more
distantly related. Finally, 4 proteins (Bbr_0651,
BIFBRE_03589, CECT7263_10981 and HMPREF9228_1217)
were annotated as containing both a protein kinase family
domain from c109925, while also containing a protein from the
Pfam07462 (merozoite surface proteins). These 4 proteins
were very highly conserved within the B. breve species sharing
>99% percentage identity, while being more distantly related to
proteins from other Bifidobacterium species, e.g.
BIFANG_02451 from B. angulatum DSM 20098, which did not
contain any protein of the Pfam07462.
We also investigated if the β-lactamases and aminoglycoside
resistant protein sequences detected in bifidobacteria, could be
classified according to the Ambler classes A-D for β-
lactamases and acetylation, adenylation and phosphorylation
enzymes for aminoglycosides. However, due to insufficient
similarity with the sequences of known β-lactamases and
aminoglycoside resistance proteins from other genera, such
classifications were not possible.
Laboratory-based assessment of the antibiotic
resistance of representative bifidobacterial strains
Laboratory tests were conducted with a number of
representative Bifidobacterium species to determine if the
presence of putative antibiotic resistance proteins
corresponded to antibiotic resistance. The specific strains used
had been determined, on the basis of the in silico screen, to
contain putative β-lactam and/or aminoglycoside resistance
genes. The use of different species and strains enabled us to
determine if the results were genus, species or strain specific.
The strains tested were B. breve UCC2003, B. breve DSM
20213, B. gallicum DSM 20093, B. animalis subsp. lactis Bb12,
B. angulatum DSM 20098 and B. pseudocatenulatum DSM
20438 (Table 2). Disc diffusion assays were performed using
both aminoglycoside [kanamycin (30µg), gentamycin (200 µg),
streptomycin (25 µg) and neomycin (30 µg)] and β-lactam
antibiotic discs [ampicillin (25 µg) and penicillin (10 µg)].
Following anaerobic incubation at 37°C for 48 hours, zones of
inhibition were measured (Table 5). All tests were performed in
triplicate. The results indicated that all strains tested were
highly sensitive to the β-lactam antibiotics tested (all zones ≥
52mm in diameter), thus establishing that the annotated β-
lactamase genes did not confer resistance to the β-lactam
antibiotics in the strains tested. Additionally, the β-lactamase
Table 3 (continued).
Bifidobacterium strain Accession number*  Gene name Assigned as Pfam
 YP_003938240.1d BBIF_0461 Metallo-beta-lactamase domain-containing protein
Metal dependent hydrolase with
PF07521
 YP_003939303.1g BBFI_1524 β-lactamase PF13354
B. pseudocatenulatum DSM 20438 ZP_03741949.1c BIFPSEUDO_02501 Hypothetical protein PF00144
 ZP_03742801.1d BIFPSEUDO_03375 Hypothetical protein Metal dependent hydrolase withPF07521
B. longum NCC2705 NP696361.1d BL_1192 Hypothetical protein Metal dependent hydrolase withPF07521
B. longum subsp. infantis ATCC 55813 ZP_03976420.1d HMPREF0175_0795 Metal dependent hydrolase Metal dependent hydrolase withPF07521
B. longum BBMN68 YP_004000557.1d BBMN68_955 Hydrolase Metal dependent hydrolase withPF07521
B. longum DJ010A YP_001954894.1d BLD_0950 Metallo-beta-lactamase superfamilyhydrolase
Metal dependent hydrolase with
PF07521
B. longum subsp. longum JCM 1217 YP_004220181.1d BLLJ_0420 Hypothetical protein Metal dependent hydrolase withPF07521
B. longum subsp. longum JDM301 YP_00366798.1d BLJ_0491 β-lactamase domain-containing protein Metal dependent hydrolase withPF07521
B. longum subsp. infantis ATCC 15697 YP_005585858.1d BLIJ_2111 Hypothetical protein Metal dependent hydrolase withPF07521
 YP_002323794.1 BLon_2358 β-lactamase PF12706 and 07521
B. animalis subsp. lactis HN019 ZP_02963481.1d BIFLAC_07662 Hypothetical protein Metal dependent hydrolase withPF07521
B. gallicum DSM 20093 ZP_05965566.1d BIFGAL_03078 Metallo-beta-lactamase family protein Metal dependent hydrolase withPF07521
B. angulatum DSM 20098 ZP_04447555.1d BIFANG_02533 Hypothetical protein Metal dependent hydrolase withPF07521
* Same superscript indicates proteins share >90% sequence percentage identity
doi: 10.1371/journal.pone.0082653.t003
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Table 4. Bifidobacterium derived aminoglycoside resistance proteins.
Bifidobacterium strain
Accession
number* Gene name Assigned as Pfam
B. longum DJ010A YP_00195405.3a BLD_0109 AG phosphotransferase Proteins containing a protein kinase family domain, c109925
 ZP_00121257.2a Blon_03001154 Hypothetical protein Proteins containing a protein kinase family domain, c109925
 ZP_00121797.2b BLD_1766 Hypothetical protein Phosphotransferase family with PF 01636 and proteinscontaining a protein kinase family domain, c109925
B. longum BBMN68 YP_003999751.1a BBMN68_137 AG phosphotransferases Phosphotransferase family with PF 01636
 YP_004001272.1b BBMN_1674 Homoserine kinase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. longum subsp. infantis
CCUG 52486 ZP_04663835.1
a BLIG_01916 Hypothetical protein Proteins containing a protein kinase family domain, c109925
 ZP_04664566.1b BLIG_01601 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. longum NCC 2705 NP695320.1a BL_0091 Hypothetical protein Proteins containing a protein kinase family domain, c109925
 NP696793.1b BL_1642 Desulfatase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. longum KACC 91563 YP_005586893.1a BLNIAS_ 00852 Hypothetical protein Proteins containing a protein kinase family domain, c109925
B. adolescentis L2-32 ZP_02029839.1i BIFADO_02300 Hypothetical protein Proteins containing a protein kinase family domain, c109925
B. longum subsp. infantis ATCC
55813 ZP_03976875.1
a HMPREF0175_1250 AG phosphotransferase Proteins containing a protein kinase family domain, c109925
B. longum subsp. infantis ATCC
15697 YP_002322254.1
a Blon_0773 AG phosphotransferase Proteins containing a protein kinase family domain, c109925
 YP_002323612.1a Blon_2173 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. longum subsp. longum
JDM301 YP_003661654.1
a BLJ_1379 AG phosphotransferases Proteins containing a protein kinase family domain, c109925
B. breve UCC2003 ABE95342.1c Bbr_0651 Conserved Hypotheticalsecreted protein
Merozoite surface protein 1 (MSP1) C-terminus of the PF
07462 and proteins containing a protein kinase family
domain, c109925
 ABE96255.1 d Bbr_1586 AG phosphotransferases Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. breve DSM 20213 ZP_06595772.1 c BIFBRE_03589 Conserved hypotheticalprotein
Merozoite surface protein 1 (MSP1) C-terminus of the PF
07462 and proteins containing a protein kinase family domain,
c109925
 ZP_06596651.1 d BIFBRE_04498 Mucin desulfating sulfatase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. breve CECT 7263 EHS85254.1 d CECT7263_14691 Mucin desulfating sulfatase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 EHS85519.1c CECT7263_10981 Hypothetical protein
Merozoite surface protein 1 (MSP1) C-terminus of the PF
07462 and proteins containing a protein kinase family domain,
c109925
B. breve ACS 071 VSch 8b YP_005583039.1c HMPREF9228_1217 Phosphotransferaseenzyme domain protein
Merozoite surface protein 1 (MSP1) C-terminus of the PF
07462 and proteins containing a protein kinase family domain,
c109925
 YP_005583418.1d HMPREF9228_1637 Putative mucin-desulfatingsulfatase
Proteins containing a protein kinase family domain, c109925
and phosphotransferase family with PF 01636
B. animalis subsp. lactis Bb12 YP_005575653.1e BIF_00526 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 YP_005576071.1f BIF_01665 AG 3' phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. dentium ATCC 27678 ZP_02918244.1g BIFDEN_01548 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. dentium Bd1 YP_003361041.1g BDP_1625 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. dentium ATCC 27679 ZP_07455726.1g HMPREF0168_0285 Conserved hypotheticalprotein
Proteins containing a protein kinase family domain, c109925
and phosphotransferase enzyme family of the PF 01636
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nitrocefin tests also demonstrated a lack of β-lactamase activity
among the bifidobacteria strains tested. In contrast, when these
strains were tested using aminoglycoside antibiotic discs, each
of the strains were shown to be highly resistant to each of the
antibiotics, i.e. zone of inhibition was small or absent (Table 5).
Disruption of the Bbr_0651 and Bbr_1586 genes of B.
breve UCC2003
An insertional inactivation approach was implemented to
determine to what extent putative aminoglycoside resistance
genes contribute to the observed aminoglycoside resistance in
bifidobacteria. B. breve UCC2003 was selected as a target,
due to the success with which gene disruptions have been
previously created in this strain [50,51]. The genes Bbr_0651
and Bbr_1586 were targeted for disruption. The gene
Bbr_0651 encodes a putative conserved hypothetical secreted
protein which shares 99% identity with other putative
phosphotransferase enzymes (e.g. BIFBRE_03589 from B.
breve DSM 20213) and also shares 71% identity with an
aminoglycoside phosphotransferase from B. longum subsp.
longum ATCC 55813 (HMPREF0175_1250). The gene
Bbr_1586 encodes a putative phosphotranferase family
enzyme, which also shares 91% identity with a putative
aminoglycoside phosphotransferase from B. longum subsp.
longum ATCC 55813 (HMPREF0175_1250).
Table 4 (continued).
Bifidobacterium strain Accession number*Gene name Assigned as Pfam
B. dentium JCVHM P022 ZP_07696282.1g HMPREF9003_0562 Conserved hypotheticalprotein
Proteins containing a protein kinase family domain, c109925
and phosphotransferase enzyme family of the PF 01636
B. catenulatum DSM 16992 ZP_03323625.1h BIFCAT_00394 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. pseudocatenulatum DSM
20435 ZP_03742521.1
h BIFPSEUDO_03094 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. adolescentis ATCC 15703 YP_910027.1i BAD_1164 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. bifidum S17 YP_003938274.1j BBIF_0495 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 YP_003938776.1k BBIF_0997 Mucin de-sulfatase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 YP_003939526.1l BBIF_1747 AG transferase Phosphotransferase enzyme family of the PF 01636 and AGphosphotransferases of the aph family cd 05150
B. bifidum PRL 2010 YP_003970614.1j BBPR_0470 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. bifidum BGN4 YP_006393921.1j BBB_0447 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 YP_006394449.1k BBB_0978 N-acetyl hexosamine kinase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. bifidum NCIMB 41171 ZP_07801902.1j BBNG_00382 Conserved hypotheticalprotein
Proteins containing a protein kinase family domain, c109925
and phosphotransferase family with PF 01636
B. angulatum DSM 20098 ZP_04447474.1m BIFANG_02451 Hypothetical protein Proteins containing a protein kinase family domain, c109925
B. animalis subsp. lactis HN019 YP_002469703.1e BLA_0835 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 ZP_02963731.1e BIFLAC_04950 Hypothetical protein Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
B. animalis subsp. animalis
ATCC 25527 YP_006280402.1
e BANAN_06155 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
 YP_006279244.1n BANAN_00270 AG phosphotransferase
Phosphotransferase family with PF 01636 and
aminoglycoside phosphotransferases of the aph family cd
05150
B. longum subsp. longum
JCM1217 YP_004221381.1
b BLLJ_1622 AG phosphotransferase Proteins containing a protein kinase family domain, c109925and phosphotransferase family with PF 01636
Bifidobacterium sp.
12_1_47BFAA ZP_07941182.1
b HMPREF0177_00575 Phosphotransferaseenzyme family protein
Proteins containing a protein kinase family domain, c109925
and phosphotransferase family with PF 01636
B. longum subsp. infantis 157F YP_004209317.1a BLIF_1400 Hypothetical protein Proteins containing a protein kinase family domain, c109925
* Same superscript indicates proteins share >90% sequence percentage identity
AG: aminoglycoside
doi: 10.1371/journal.pone.0082653.t004
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To determine if disruptions to the genes Bbr_0651 and
Bbr_1586 which encode putative aminoglycoside resistance
proteins impact on the aminoglycoside resistant phenotype of
B. breve UCC2003, disc diffusion assays were carried out.
Zones of inhibition were measured and compared to the wild-
type, B. breve UCC2003. Differences in the inhibition zones
were noted between the mutants and the wild-type, suggesting
reduced aminoglycoside resistance in the mutants as
compared to the wild-type B. breve UCC2003 (Table 5).
Additionally, MICs were performed to compare aminoglycoside
resistance of the wild-type to that of the two insertion mutants.
As shown in Table 6, after 24 hours incubation, the insertion
mutants were more sensitive to gentamycin, streptomycin and
kanamycin, but not neomycin, as compared to the wild-type
strain. These results thereby demonstrate that both Bbr_0651
and Bbr_1586 contribute to aminoglycoside resistance and can
be assigned as aminoglycoside resistance determinants. To
verify that the observed changes to phenotype were as a direct
result of disruption to the genes Bbr_0651 and Bbr_1586,
rather than as an indirect consequence of the mutagenesis
strategy, MICs were conducted on another insertion mutant
created in B. breve UCC2003, namely B. breve UCC2003-
gosG [51]. This mutant was created previously using the same
protocol that was used to create the mutants Bbr_0651 and
Bbr_1586, but in this instance the Bbr_0529 (gosG) gene is
disrupted. The antibiotic resistance phenotype of this mutant
was similar to that of the wild-type B. breve UCC2003 (Table
6).
Table 5. Antibiotic resistance of bifidobacteria strains as
assessed through antibiotic disc assays.
Antibiotic (microgram/per disc)
 β-lactams Aminoglycosides
Bifidobacteria species AMP 25
PEN 10
IU KAN 30 GEN 200STR 25 NEO 30
B. breve DSM 20213 71mm 65mm No zone 22mm 16mm 14mm
B. animalis subsp. lactis
Bb12 65mm 55mm No zone 28mm 21mm 20mm
B. pseudocatenulatum
DSM 20438 61mm 56mm 8mm 10mm 13mm 20mm
B. gallicum DSM 20093 60mm 59mm No zone 24mm 30mm 10mm
B. angulatum DSM 20098 64mm 65mm 4mm 23mm 16mm 10mm
B. breve UCC2003 67mm 56mm No zone 26mm 21mm 10mm
B. breve UCC2003-0651-
tet 52mm 57mm 10mm 40mm 33mm 14mm
B. breve UCC2003-1586-
tet 62mm 57mm 9mm 41mm 31mm 15mm
B. breve UCC2003-1586-
tet-pBC1.2-Bbr_1586 62mm 59mm No zone 30mm 33mm 13mm
AMP, ampicillin; PEN, penicillin; KAN, kanamycin; GEN, gentamycin; STR,
streptomycin; NEO, neomycin
Values are average of triplicate plate results (SD±1mm for all samples, on all
antibiotics)
doi: 10.1371/journal.pone.0082653.t005
To further confirm that the observed reduction in
aminoglycoside resistance of the insertion mutant was as a
direct result of disruption to the putative AG resistance
proteins, complementation studies were performed with one of
the mutants. The MIC results demonstrate that following
complementation, the resistance of the insertion mutant
Bbr_1586 was restored to levels almost identical to those of the
wild-type (Table 6). Additionally, MICs were determined upon
addition of extra plasmid-encoded copies of the putative
aminoglycoside resistance genes Bbr_0651, Bbr_0651+0650
or Bbr_1586 into wild-type B. breve UCC2003 to determine if
enhanced resistance to aminoglycosides would occur (Table
6). The results established that the addition of the construct
pBC1.2-Bbr_1586 resulted in a 2-fold increased resistance to
both streptomycin and kanamycin, relative to that of the
parental strain. No increase in resistance to either gentamycin
or neomycin was observed. Furthermore, the addition of either
pBC1.2-Bbr_0651+0650 or pBC1.2-Bbr_0651 did not increase
the resistance of UCC2003 to any of the tested
aminoglycosides. Finally, the introduction of Bbr_0651 or
Bbr_0651+0650 into E. coli XL1-blue resulted in a 2-fold
increased resistance to gentamycin and neomycin, while the
introduction of Bbr_1586 also increased resistance to
neomycin by 2-fold, relative to the control E. coli XL1-blue-
pBC1.2 strain (Table 6).
Table 6. MIC values (mg/L) of wild-type B. breve UCC2003
compared to mutants as determined by broth micro-dilution
assay (MRS+cysteine for Bifidobacterium and LB broth for
E. coli cultures).
 Antibiotic (mg/L)
 GEN NEO STR KAN
Sample 1-1024 1-1024 2-4096 2-4096
B. breve UCC2003 wild-type >1024 >1024 1024 >4096
B. breve UCC2003-0651-tet 256 >1024 256 1024
B. breve UCC2003-1586-tet 256 >1024 256 1024
B. breve UCC2003-gosG >1024 >1024 2048 >4096
B. breve UCC2003-1586-tet-pBC1.2-
Bbr_1586 >1024 1024 256 4096
B. breve UCC2003 wild-type* 4096 4096 1024 4096
B. breve UCC2003-pBC1.2_Bbr_1586* 4096 4096 2048 8192
B. breve UCC2003-pBC1.2_Bbr_0651* 4096 4096 1024 4096
B. breve UCC2003-pBC1.2_Bbr_0651+0650* 4096 4096 1024 4096
E. coli XL1-blue-pBC1.2 <1 4 <2 <2
E. coli XL1-blue-pBC1.2_Bbr_0651+0650 2 8 <2 <2
E. coli XL1-blue-pBC1.2_Bbr_0651 2 8 <2 <2
E. coli XL1-blue-pBC1.2_Bbr_1586 <1 8 <2 <2
GEN, gentamycin; NEO, neomycin; STR, streptomycin; KAN, kanamycin
Values based on triplicate readings, which were identical in all cases
* Higher ranges of antibiotics used to test effect of additional gene copies on MICs
compared to wild-type (High range used: 256-16384mg/L for Gent/Neo;
1024-65536mg/L for Strep/Kan)
doi: 10.1371/journal.pone.0082653.t006
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Discussion
The human microbiota contributes to numerous vital gut
functions including nutrient metabolism, vitamin biosynthesis
and immune system development [52]. However, it has more
recently been postulated that this complex microbial population
is also a sizeable reservoir for antibiotic resistance genes
[53,54], and that microbes containing such genes can become
dominant in the human gastrointestinal tract following antibiotic
exposure [36,55,56]. There is also a risk that such genes could
be transferred to other microbes, including those passing
through the gastrointestinal tract, and thus could contribute to
the dissemination of antibiotic resistance genes [53].
Commensal bifidobacteria have received significant attention
as a consequence of frequent reports of the beneficial impact
of particular species or strains on health [25,57,58], with only
one species, B. dentium, being a known human (cariogenic)
pathogen [59]. Furthermore, given the frequent use of
Bifidobacterium strains as probiotics, any association between
these microbes and potentially transferrable antibiotic
resistance would be a cause for concern.
Several studies have utilised culture-based approaches to
determine the resistance or sensitivity of bifidobacteria to
various families of antibiotics, though the genetics underlying
this resistance has not been examined extensively
[29,31,35,43]. The exceptional studies that exist have focused
on mutations to genes encoding specific targets and the
resulting increased antibiotic resistance. In one instance the
genetic basis for the enhanced resistance of mutants of B.
bifidum Yakult strain YIT4007 was investigated [32]. Briefly,
YIT 4007 was isolated from the progenitor strain YIT 4001 by
screening mutants of YIT 4001 for enhanced resistance to
neomycin, erythromycin and streptomycin. To investigate the
potential transfer of resistance, genetic tests on the mutants
were also performed. The study identified several
chromosomal mutations, namely mutations on 3 copies of the
23S ribosomal RNA genes, an 8bp deletion of the rluD gene
and a mutation on the rspL gene, which they considered to be
responsible for the observed increased resistance to
aminoglycoside antibiotics, at levels at which the progenitor
strain was sensitive. As these mutations were not located on
mobile genetic elements, it was concluded that this strain
posed no risk of antibiotic resistance transfer. Another study
investigated antibiotic resistance levels in 26 B. breve strains
and found that a Yakult probiotic strain demonstrated atypically
high resistance to streptomycin [37]. Genetic analysis
determined that a mutation to the rpsL gene, which encodes
the ribosomal protein S12, was responsible. In light of the
general rarity of studies investigating the genetic basis for
innate aminoglycoside resistance in bifidobacteria, this study
examined the contribution of in silico assigned aminoglycoside
resistance proteins to the resistance phenotype of
bifidobacteria. Indeed, to our knowledge, ours is the first study
that utilises a targeted in silico based approach to assess the
existence and prevalence of putative β-lactamase and
aminoglycoside resistance proteins in the Bifidobacterium
genus and to subsequently investigate if representative genes
confer a resistant phenotype.
With respect to the putative β-lactamases, it was noted that
several proteins of potential relevance have been assigned
across the Bifidobacterium genus. However, none of these
were clear representatives of any of the Ambler classes of β-
lactamases. When all of the sequences were considered it
appeared they could be grouped broadly into one of three
groups, i.e. those which were members of Pfam 00144, those
of Pfam 07521 or Pfam 12706. Most frequently these
sequences were annotated as hypothetical proteins, while
others were annotated as β-lactamases. To detect such a high
prevalence of putative β-lactamases amongst bifidobacteria
was surprising given that previous laboratory based
investigations have shown bifidobacteria to be sensitive to
commonly prescribed β-lactams [29,31,35,43,60]. Indeed, for
example, in 2010 Xiao et al. demonstrated that 23 investigated
bifidobacterial strains were sensitive to all β-lactams tested
[31]. In order to examine whether these annotated β-lactamase
sequences resulted in a resistance phenotype, we selected a
representative number of bifidobacteria strains, which had
been identified in the in silico screen as containing putative β-
lactamases, and studied these further. Using a culture-based
approach, the results indicated that none of the representative
bifidobacterial strains which were tested were resistant to the
β-lactam antibiotics. These results draw into question the
significance of the high frequency of putative β-lactamases or
hypothetical proteins closely related to β-lactamases in
bifidobacteria genomes. The fact that the tested bifidobacteria
were sensitive to β-lactam antibiotics and showed no β-
lactamase activity (as assessed using the nitrocefin test),
despite the presence of annotated β-lactams in their genome,
as well as the lack of sequence homology when compared to
known β-lactamase sequences, led us to conclude that this is
most likely due to significant mis-annotation of protein
sequences across publically available Bifidobacterium
genomes. Alternatively, it could be proposed that these β-
lactamase genes are repressed in bifidobacteria. While this
possibility could be assessed by expression-based studies,
which may be investigated in future studies, we think it more
likely that the mis-annotation of these putative resistance
genes is the basis for the absence of resistance. Indeed, there
are previous examples of the mis-assignment of genes as
penicillin resistance genes, such as the mis-annotation of the
bile salt hydrolase genes as penicillin acylases [61,62]. With
the development of high-throughput genome sequencing
methods, automated approaches to annotation became
increasingly popular [63]. However, this study provides an
example of how mis-annotation of the first bifidobacteria
genomes has led to further mis-annotation of subsequent
genome sequences. Notably, several studies have investigated
the extent of mis-annotation of genomes and noted the
frequency of this issue [64-67], with one study finding an 8%
error rate across just 340 genes [65]. Such an approach, which
is likely to continue as sequencing becomes even more
efficient and cost effective, and is coupled to automated
annotation, could cause undue concern about the safety of a
species, for example, in the case where antibiotic resistance
protein sequences are detected in a potential probiotic
bacterium. Thus, our results highlight the necessity for
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laboratory-based investigations into the function of annotated
proteins.
Various culture-based studies have demonstrated that
bifidobacteria are resistant to the aminoglycoside family of
antibiotics [29,31,35]. This phenomenon was also apparent in
the representative strains employed for this study. This
resistance has been suggested to be due to the absence of
appropriate cytochrome-mediated transport systems in
bifidobacteria for aminoglycoside uptake [68]. This theory was
first proposed in 1979, when it was demonstrated that
Bacteroides fragilis and Clostridium perfringens were resistant
to aminoglycoside antibiotics due to an inability to synthesize
cytochrome structures and thus cannot utilise electron
transport mediated transfer that is proposed to facilitate the
entry of aminoglycosides into the cells [68]. It has since been
accepted that bifidobacteria are intrinsically resistant to
aminoglycoside antibiotics by the same mechanism [69].
However, we hypothesized that the resistance proteins
detected in our in silico screen could be providing additional
resistance beyond this intrinsic resistance and thus could
contribute to the survival of bifidobacteria at higher
concentrations of aminoglycosides.
The in silico screen highlighted the prevalence of putative
aminoglycoside resistance proteins across members of the
Bifidobacterium genus. Though a high frequency of
aminoglycoside resistance proteins and related hypothetical
proteins were detected, the sequences could be broadly
categorised as those which were members of the Pfam 01636,
those containing a protein kinase family domain c109925 and
those which belonged to the Pfam 01636 and contained the
domain c109925. To investigate the hypothesis that these
putative resistance proteins contribute to aminoglycoside
resistance in bifidobacteria, putative aminoglycoside resistance
genes from one strain were mutated. More specifically, using
B. breve UCC2003 as a representative strain, we disrupted the
2 genes present in this strain, which were detected in the in
silico screen as being the genes potentially encoding
aminoglycoside resistance proteins. Following confirmation that
successful homologous recombination had occurred (at the
targeted gene specific sites) within B. breve UCC2003,
aminoglycoside resistance of the respective mutants was
tested. These experiments demonstrated that disruption of
either of these 2 aminoglycoside resistance genes impacted on
the resistance phenotype of B. breve UCC2003 (Table 5).
Thus, we propose that while the lack of cytochrome-mediated
transport of the aminoglycosides into the cells may be an
important contributor to the observed resistance phenotype
among bifidobacteria and alone are sufficient to result in the
strains being considered to be clinically resistant, these
annotated aminoglycoside resistance proteins are true
aminoglycoside resistance proteins, which further enhance this
intrinsic resistance. To investigate this hypothesis further, MICs
were conducted to compare the resistance of the mutants
compared to the wild-type at higher levels of aminoglycoside
antibiotics. The results established that the mutants exhibited
greater sensitivities to gentamycin, streptomycin and
kanamycin compared to the wild-type strain (Table 6).
Unfortunately, the strategy employed precluded the creation of
a double mutant that lacks both Bbr_1586 and Bbr_0651.
Should methods be developed to create deletion mutants in
Bifidobacterium in the future, such a mutant can be created in
order to determine if the inactivation of both aminoglycoside
resistance genes results in a more pronounced aminoglycoside
sensitive phenotype. Through complementation studies, it was
demonstrated that reintroduction of the Bbr_1586 gene
restored resistance to gentamycin and kanamycin to levels
which were essentially identical to those of the wild-type (Table
6). Additionally, when an extra, plasmid-borne copy of the gene
Bbr_1586 was added to wild-type B. breve UCC2003, a 2-fold
increased resistance was seen for streptomycin and
kanamycin. However, additional copies of Bbr_1586 did not
enhance resistance of the wild-type B. breve UCC2003 to
neomycin and gentamycin. This may be due to the fact that the
resistance of the wild-type to these antibiotics was already high
(Table 6), and thus the aminoglycoside resistance proteins may
have been saturated or unable to provide additional resistance
to such high levels of antibiotics. Moreover, when an additional
copy of either Bbr_0651+0650 or Bbr_0651 was added to the
wild-type B. breve UCC2003, no additional enhanced
resistance occurred for any of the aminoglycosides tested. This
suggests that the genome-encoded copy of this gene is already
performing its function optimally. The results in relation to
Bbr_1586 and streptomycin resistance are puzzling in that,
while disruption to the putative aminoglycoside resistance
genes resulted in a reduction in streptomycin resistance and
additional plasmid-encoded copies of these genes increased
the resistance to streptomycin compared to wild-type levels,
complementation failed to restore streptomycin levels to those
seen in the wild-type. One possible explanation is that there
are additional genes downstream of Bbr_1586, which
contribute to streptomycin resistance and are impacted upon in
a polar manner following mutagenesis by plasmid insertion.
The role of Bbr_0651 and Bbr_1586 as aminoglycoside
resistance determinants was further confirmed through the
provision of enhanced protection against at least one
aminoglycoside upon their expression in E. coli XL1-blue.
Ultimately, it is evident that both Bbr_0651 and Bbr_1586
contribute to aminoglycoside resistance in B. breve UCC2003.
Importantly however, given that these resistance genes are not
located on or near mobile genetic elements, they are unlikely to
pose a risk of transferring antibiotic resistance to other bacteria
populations. In fact it may be beneficial for species of
Bifidobacterium to possess such non-transferable
aminoglycoside resistance genes. Such species would survive
higher levels of aminoglycosides than species without this
additional genetic resistance, and so they may be more
suitable as potential probiotics for use during aminoglycoside
therapy. The results of this study re-emphasise the fact that
annotation of genomes is a predictive process and that the
results generated must be interpreted cautiously. Nonetheless,
this approach did accurately predict the presence of
aminoglycoside resistance proteins in bifidobacterial genomes.
Crucially, laboratory based experiments were carried out to
validate these annotations and similar such laboratory
experiments are required to assess other putative antibiotic
resistance genes in bifidobacteria and other genera.
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